Hemophilia ANews & Research
17 curated articles for Hemophilia A — FDA updates, peer-reviewed research, clinical-trial milestones, and sponsor press releases. Sorted newest-first.
- Journal of investigational allergology & clinical immunology Apr 21, 2026
Acquired Hemophilia A Following Omalizumab Treatment in a Patient With Chronic Spontaneous Urticaria.
Acquired Hemophilia A Following Omalizumab Treatment in a Patient With Chronic Spontaneous Urticaria.
Why it matters: Recent peer-reviewed research on Hemophilia A that may be relevant for patients and caregivers.
- Hamostaseologie Apr 21, 2026
Perioperative Management for Port Catheter Procedures in Pediatric Patients with Severe Hemophilia and Inhibitors.
The objective of this systematic study was to assess the perioperative management and outcome of surgery in pediatric patients with hemophilia A/B and inhibitors compared to nonhemophilic pediatric patients. The surgical outcome of 69 port catheter operations in patients with hemophilia who develope...
Why it matters: Recent peer-reviewed research on Hemophilia A that may be relevant for patients and caregivers.
- Archives of medical research Apr 17, 2026
Factor VIII Pharmacokinetics in Mexican Patients with Hemophilia A.
Treatment of patients with severe hemophilia A requires the replacement of deficient factor VIII. To reach the international standards of care, an optimal dose of factor VIII should be administered based on pharmacokinetic analysis. However, in Mexico factor VIII pharmacokinetics is not used. Theref...
Why it matters: Recent peer-reviewed research on Hemophilia A that may be relevant for patients and caregivers.
- La Revue du praticien Mar 31, 2026
[Acquired hemophilia A].
[Acquired hemophilia A].
Why it matters: Recent peer-reviewed research on Hemophilia A that may be relevant for patients and caregivers.
- BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy Mar 25, 2026
Immunogenicity of Gene and Cell Therapies.
Gene and cell therapies have been gaining popularity with market approvals by the US Food and Drug Administration, European Medicines Agency, and other regulatory bodies. Adeno-associated viral vector gene therapies approved for rare inherited diseases and chimeric antigen receptor T-cell therapies ...
Why it matters: Recent peer-reviewed research on Hemophilia A that may be relevant for patients and caregivers.
- Expert review of clinical pharmacology Mar 16, 2026
Factor-VIII mimetic bispecific antibodies for the treatment of hemophilia A: an update.
Bispecific antibodies are used to treat various conditions, with notable results in hemophilia A, a rare bleeding disorder characterized by reduced or absent activity of the coagulation factor VIII (FVIII). Emicizumab is a bispecific antibody that mimics FVIII activity, reducing bleeds in people wit...
Why it matters: Recent peer-reviewed research on Hemophilia A that may be relevant for patients and caregivers.
- Seminars in thrombosis and hemostasis Mar 9, 2026
Emicizumab in Acquired Hemophilia A: Benefits in Bleed Control, Safety, and Cost-Effectiveness.
Emicizumab in Acquired Hemophilia A: Benefits in Bleed Control, Safety, and Cost-Effectiveness.
Why it matters: Recent peer-reviewed research on Hemophilia A that may be relevant for patients and caregivers.
- Journal of thrombosis and haemostasis : JTH Mar 7, 2026
Overview of gene therapy for hemophilia: questions and answers to navigate the innovation.
Hemophilia is a rare inherited bleeding disorder affecting approximately 1.1 million individuals worldwide, characterized by deficiency in clotting factor (F)VIII (hemophilia A) or FIX (hemophilia B). Despite advances in prophylactic factor replacement therapy and nonfactor treatments, persons with ...
Why it matters: Recent peer-reviewed research on Hemophilia A that may be relevant for patients and caregivers.
- Annals of hematology Mar 6, 2026
Emicizumab in the treatment of acquired hemophilia A: A Two-Center experience.
Emicizumab is a FVIII mimetic antibody used in the treatment of inherited hemophilia A that could potentially be used in acquired hemophilia A (AHA) to achieve hemostasis and shorten hospital stay while reducing bypass therapies. We report on 12 cases of AHA patients treated with emicizumab in an ac...
Why it matters: Recent peer-reviewed research on Hemophilia A that may be relevant for patients and caregivers.
- Journal of thrombosis and haemostasis : JTH Mar 6, 2026
T cells from individuals with and without hemophilia A respond to the same epitopes in factor VIII.
Development of neutralizing anti-factor [F]VIII antibodies (inhibitors) follows recognition by CD4 + T cells of epitopes that are presented on the individual's human leukocyte antigen (HLA) class II. Limited blood volumes have presented a major challenge in mapping T-cell epitopes in FVIII, especial...
Why it matters: Recent peer-reviewed research on Hemophilia A that may be relevant for patients and caregivers.
- Blood Mar 5, 2026
Efficacy and safety of marstacimab prophylaxis in hemophilia A/B with inhibitors: results from the phase 3 BASIS trial.
Marstacimab, a monoclonal antibody that inhibits tissue factor pathway inhibitor, is approved for prophylactic use in individuals with hemophilia A or B without inhibitors. We present efficacy and safety for individuals with inhibitors. The open-label, single-arm, phase 3 study evaluated once-weekly...
Why it matters: Recent peer-reviewed research on Hemophilia A that may be relevant for patients and caregivers.
- International journal of molecular sciences Feb 24, 2026
Challenges in Balancing Hemostasis and Thrombosis in Therapy Tailoring for Hemophilia: A Narrative Review.
Hemostasis and thrombosis reflect a delicate balance, regulated by the interplay between procoagulant and anticoagulant mechanisms. Hemophilia is traditionally viewed as a bleeding disorder, but emerging evidence highlights the paradoxical risks of thrombosis in hemophilia patients. We explore the l...
Why it matters: Recent peer-reviewed research on Hemophilia A that may be relevant for patients and caregivers.
- Hamostaseologie Feb 17, 2026
Thrombin Generation Assays: Possibilities and Limitations.
Thrombin generation assays (TGA) provide a dynamic and integrative assessment of thrombin generation in clotting plasma ex vivo. The method is characterized by triggering coagulation, typically via the extrinsic pathway, and continuously measuring thrombin activity using a fluorogenic peptide substr...
Why it matters: Recent peer-reviewed research on Hemophilia A that may be relevant for patients and caregivers.
- mBio Feb 11, 2026
mGem: AAV, from almost a virus to an awesome vector-or is it?
Adeno-associated virus (AAV) vectors have taken center stage for gene therapy and have shown clinical efficacy in 15 human diseases to date. The Food and Drug Administration has approved seven AAV "drugs" for one-time treatment respectively for Leber's congenital amaurosis, spinal muscular atrophy, ...
Why it matters: Recent peer-reviewed research on Hemophilia A that may be relevant for patients and caregivers.
- Seminars in thrombosis and hemostasis Feb 10, 2026
Thrombotic Complications in Hemophilia: An Intricate Conundrum.
Hemophilia A and hemophilia B are rare genetic disorders characterized by low plasma levels of coagulation factor VIII or factor IX, resulting in a bleeding tendency with a clinical severity proportional to the degree of the clotting factor deficiency. Although rare, hemophilia patients can paradoxi...
Why it matters: Recent peer-reviewed research on Hemophilia A that may be relevant for patients and caregivers.
- BreakingFDA Oct 25, 2025
Hemlibra Expanded Indication Approved for All Hemophilia A
FDA approved expanded indication for Hemlibra covering all severity levels regardless of inhibitor status.
Why it matters: Broadens access to the most widely used hemophilia A prophylaxis.
- NotableBlood Oct 20, 2025
Hemophilia A Gene Therapy Shows Durable Response at 3 Years
Three-year follow-up data for valoctocogene roxaparvovec shows sustained factor VIII expression and significant reduction in bleeding events.
Why it matters: Gene therapy may offer functional cure for severe hemophilia A.
More on Hemophilia A
Articles aggregated from peer-reviewed journals (PubMed), sponsor press releases, SEC 8-K filings, and FDA announcements. Original-source links are preserved on each article page. Editorial tags (Breaking / Notable / Update) reflect UniteRare's curation-time priority assessment.